David B. Whitman

1.1k total citations
7 papers, 222 citations indexed

About

David B. Whitman is a scholar working on Immunology and Allergy, Oncology and Immunology. According to data from OpenAlex, David B. Whitman has authored 7 papers receiving a total of 222 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Immunology and Allergy, 2 papers in Oncology and 2 papers in Immunology. Recurrent topics in David B. Whitman's work include Cell Adhesion Molecules Research (4 papers), Immune Response and Inflammation (2 papers) and Bone health and treatments (1 paper). David B. Whitman is often cited by papers focused on Cell Adhesion Molecules Research (4 papers), Immune Response and Inflammation (2 papers) and Bone health and treatments (1 paper). David B. Whitman collaborates with scholars based in United States. David B. Whitman's co-authors include George D. Hartman, Mark E. Duggan, Gideon A. Rodan, Sevgi B. Rodan, James J. Perkins, Paul J. Coleman, Christopher D. Cox, William F. Hoffman, Joel R. Huff and Gregg Wesolowski and has published in prestigious journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters and Medicinal Chemistry Research.

In The Last Decade

David B. Whitman

7 papers receiving 212 citations

Peers

Countries citing papers authored by David B. Whitman

Since Specialization

Citations

This map shows the geographic impact of David B. Whitman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Whitman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Whitman more than expected).

Fields of papers citing papers by David B. Whitman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Whitman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Whitman. The network helps show where David B. Whitman may publish in the future.

Co-authorship network of co-authors of David B. Whitman

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Whitman. A scholar is included among the top collaborators of David B. Whitman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Whitman. David B. Whitman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Amide- and bis-amide-linked highly potent and broadly active antifungal agents for the treatment of invasive fungal infections- towards the discovery of pre-clinical development candidate FC12406 2023 ·Medicinal Chemistry Research ·Simon D. P. Baugh, (unknown), (unknown), David B. Whitman, Jeffrey C. Pelletier, (unknown), Katie B. Freeman, Allen B. Reitz, Richard W. Scott	2
2	Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding 2009 ·Bioorganic & Medicinal Chemistry Letters ·Christopher D. Cox, Georgia B. McGaughey, Michael J. Bogusky, David B. Whitman, Richard G. Ball, Christopher J. Winrow, John J. Renger, Paul J. Coleman	43
3	Kinesin spindle protein (KSP) inhibitors. Part V: Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein 2007 ·Bioorganic & Medicinal Chemistry Letters ·Christopher D. Cox, Michael J. Breslin, David B. Whitman, Paul J. Coleman, R. M. Garbaccio, Mark E. Fraley, Matthew M. Zrada, Carolyn A. Buser, Eileen S. Walsh, Kelly Hamilton, Robert B. Lobell, Weikang Tao, Marc Abrams, Vicki J. South, Hans E. Huber, Nancy E. Kohl, George D. Hartman	39
4	Nonpeptide αvβ3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone 2004 ·Bioorganic & Medicinal Chemistry Letters ·David B. Whitman, Ben Askew, Le T. Duong, Carmen Fernández‐Metzler, Wasyl Halczenko, George D. Hartman, John H. Hutchinson, Chih‐Tai Leu, Thomayant Prueksaritanont, Gideon A. Rodan, Sevgi B. Rodan, Mark E. Duggan	6
5	Non-Peptide αvβ3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics 2002 ·Bioorganic & Medicinal Chemistry Letters ·Paul J. Coleman, Ben Askew, John H. Hutchinson, David B. Whitman, James J. Perkins, George D. Hartman, Gideon A. Rodan, Chih‐Tai Leu, Thomayant Prueksaritanont, Carmen Fernández‐Metzler, (unknown), Robert J. Lynch, Joseph J. Lynch, Sevgi B. Rodan, Mark E. Duggan	26
6	Nonpeptide αvβ3 antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide 2002 ·Bioorganic & Medicinal Chemistry Letters ·Robert Meißner, James J. Perkins, Le T. Duong, George D. Hartman, William F. Hoffman, Joel R. Huff, Nathan C. Ihle, (unknown), Rose Marie Nagy, Adel M. Naylor-Olsen, Gideon A. Rodan, Sevgi B. Rodan, David B. Whitman, Gregg Wesolowski, Mark E. Duggan	38
7	Nonpeptide α_vβ₃ Antagonists. 1. Transformation of a Potent, Integrin-Selective α_IIbβ₃ Antagonist into a Potent α_vβ₃ Antagonist 2000 ·Journal of Medicinal Chemistry ·Mark E. Duggan, Le T. Duong, John Fisher, Terence G. Hamill, William F. Hoffman, Joel R. Huff, Nathan C. Ihle, Chih‐Tai Leu, Rose Marie Nagy, James J. Perkins, Sevgi B. Rodan, Gregg Wesolowski, David B. Whitman, (unknown), Gideon A. Rodan, George D. Hartman	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact